# Amantadine Therapy for Cognitive Impairment in Long COVID

> **NCT06055244** · PHASE2 · COMPLETED · sponsor: **Ohio State University** · enrollment: 64 (actual)

## Conditions studied

- Long COVID
- Post-COVID19 Condition
- Post-Acute COVID19 Syndrome

## Interventions

- **DRUG:** Amantadine

## Key facts

- **NCT ID:** NCT06055244
- **Lead sponsor:** Ohio State University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-07
- **Primary completion:** 2025-12-11
- **Final completion:** 2025-12-29
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2026-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06055244

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06055244, "Amantadine Therapy for Cognitive Impairment in Long COVID". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06055244. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*